Search

Your search keyword '"Czogala, Malgorzata"' showing total 15 results
Start Over Author "Czogala, Malgorzata"
15 results on '"Czogala, Malgorzata"'

1. Hypodiploidy has unfavorable impact on survival in pediatric acute myeloid leukemia: an I-BFM Study Group collaboration

Author

Hammer, Anne Sofie Borg, Juul-Dam, Kristian Løvvik, Sandahl, Julie Damgaard, Abrahamsson, Jonas, Czogala, Malgorzata, Delabesse, Emmanuelle, Haltrich, Iren, Jahnukainen, Kirsi, Kolb, E. Anders, Kovács, Gábor, Leverger, Guy, Locatelli, Franco, Masetti, Riccardo, Noren-Nyström, Ulrika, Raimondi, Susana C., Rasche, Mareike, Reinhardt, Dirk, Taki, Tomohiko, Tomizawa, Daisuke, Zeller, Bernward, Hasle, Henrik, and Kjeldsen, Eigil

Published
2023
Full Text
View/download PDF

2. Gemtuzumab ozogamicin for relapsed or primary refractory acute myeloid leukemia in children—the Polish Pediatric Leukemia and Lymphoma Study Group experience

Author

Pawinska-Wasikowska, Katarzyna, primary, Czogala, Malgorzata, additional, Skoczen, Szymon, additional, Surman, Marta, additional, Rygielska, Monika, additional, Ksiazek, Teofila, additional, Pac, Agnieszka, additional, Wieczorek, Aleksandra, additional, Skalska-Sadowska, Jolanta, additional, Samborska, Magdalena, additional, Wachowiak, Jacek, additional, Chaber, Radoslaw, additional, Tomaszewska, Renata, additional, Szczepanski, Tomasz, additional, Zielezinska, Karolina, additional, Urasinski, Tomasz, additional, Moj-Hackemer, Malgorzata, additional, Kalwak, Krzysztof, additional, Kozlowska, Marta, additional, Irga-Jaworska, Ninela, additional, Balwierz, Walentyna, additional, and Bukowska-Strakova, Karolina, additional

Published
2023
Full Text
View/download PDF

3. Prognostic impact of t(16;21)(p11;q22) and t(16;21)(q24;q22) in pediatric AML: a retrospective study by the I-BFM Study Group

Author

Noort, Sanne, Zimmermann, Martin, Reinhardt, Dirk, Cuccuini, Wendy, Pigazzi, Martina, Smith, Jenny, Ries, Rhonda E., Alonzo, Todd A., Hirsch, Betsy, Tomizawa, Daisuke, Locatelli, Franco, Gruber, Tanja A., Raimondi, Susana, Sonneveld, Edwin, Cheuk, Daniel K., Dworzak, Michael, Stary, Jan, Abrahamsson, Jonas, Arad-Cohen, Nira, Czogala, Malgorzata, De Moerloose, Barbara, Hasle, Henrik, Meshinchi, Soheil, van den Heuvel-Eibrink, Marry, and Zwaan, C. Michel

Published
2018
Full Text
View/download PDF

4. Gemtuzumab ozogamicin for relapsed or primary refractory acute myeloid leukemia in children--the Polish Pediatric Leukemia and Lymphoma Study Group experience.

Author

Pawinska-Wasikowska, Katarzyna, Czogala, Malgorzata, Skoczen, Szymon, Surman, Marta, Rygielska, Monika, Ksiazek, Teofila, Pac, Agnieszka, Wieczorek, Aleksandra, Skalska-Sadowska, Jolanta, Samborska, Magdalena, Wachowiak, Jacek, Chaber, Radoslaw, Tomaszewska, Renata, Szczepanski, Tomasz, Zielezinska, Karolina, Urasinski, Tomasz, Moj-Hackemer, Malgorzata, Kalwak, Krzysztof, Kozlowska, Marta, and Irga-Jaworska, Ninela

Subjects
ACUTE myeloid leukemia, CHILDHOOD cancer, HEMATOPOIETIC stem cell transplantation, HEPATIC veno-occlusive disease, LIVER enzymes, BONE marrow
Abstract

Background: Gemtuzumab ozogamicin (GO), one of the first targeted drugs used in oncology, consists of an anti-cluster of differentiation 33 (CD33) monoclonal antibody bound to a derivative of cytotoxic calicheamicin. After the drug withdrawn in 2010 due to a significantly higher rate of early deaths, GO regained approval in 2017 for the treatment of newly diagnosed, refractory, or relapsed acute myeloid leukemia (AML) in adults and children over 15 years of age. The objective of the study was a retrospective analysis of clinical characteristics, treatment outcomes, and GO toxicity profile in children with primary refractory or relapsed (R/R) AML treated in Poland from 2008 to 2022. Methods: Data were collected through the Polish Registry of Acute Myeloid Leukemia. From January 2008 to December 2022, 35 children with R/R AML were treated with GO in seven centers of the Polish Pediatric Leukemia and Lymphoma Study Group. Results: Most of the children (30 of 35) received only one GO cycle in combination with various chemotherapy cycles (IDA-FLA, DOXO-FLA, FLA, FLAG, and others). Eighteen children (51%) achieved complete remission (CR), 14 did not respond to treatment, and three progressed. GO therapy was followed by allogeneic hematopoietic stem cell transplantation (allo-HSCT) in 18 children in CR. The 5-year overall survival (OS) after GO therapy was 37.1% ± 8.7% for the total cohort. There was a trend toward a superior outcome in patients with strong expression of CD33 expression (over 50% positive cells) compared with that in patients with lower expression of CD33 (OS, 41.2% ± 11.9% versus 27.8% ± 13.2%; p = 0.5; 5-year event-free survival, 35.4% ± 11.6% versus 25.7% ± 12.3%; p = 0.5, respectively). Children under 15 years have better outcome (OS, 34.9% ± 10.4% versus 30% ± 14.5%, p = 0.3). The most common adverse events were bone marrow aplasia, fever of unknown origin, infections, and elevated liver enzyme elevation. Sinusoidal obstruction syndrome occurred in two children. Conclusions: The use of GO in severely pretreated children, including those under 15 years of age, with previous failure of AML treatment is a feasible and effective bridging therapy to allo-HSCT with an acceptable toxicity profile. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

6. Monitoring of the treatment with L-asparaginase in children with acute lymphoblastic leukemia – focus on silent inactivation and its influence on the treatment outcome

Author

Czogala, Malgorzata, primary, Rogatko, Iwona, additional, Pawińska-Wąsikowska, Katarzyna, additional, Czogała, Wojciech, additional, Bal, Wioletta, additional, Ciebiera, Małgorzata, additional, Chaber, Radosław, additional, Chodała-Grzywacz, Agnieszka, additional, Karolczyk, Grażyna, additional, Sztefko, Krystyna, additional, Balwierz, Walentyna, additional, and Skoczeń, Szymon, additional

Published
2022
Full Text
View/download PDF

7. Monitoring of treatment with L-asparaginase in children with acute lymphoblastic leukaemia, with a focus on silent inactivation and its influence on the treatment outcome.

Author

Czogala, Malgorzata, Rogatko, Iwona, Pawińska-Wąsikowska, Katarzyna, Czogała, Wojciech, Bal, Wioletta, Ciebiera, Małgorzata, Chaber, Radosław, Chodała-Grzywacz, Agnieszka, Karolczyk, Grażyna, Sztefko, Krystyna, Balwierz, Walentyna, and Skoczeń, Szymon

Subjects
*ASPARAGINASE, *LYMPHOBLASTIC leukemia, *ALLERGIES, *MEDICAL care, *HEALTH outcome assessment
Abstract

Introduction: The aim of the study was to analyse the frequency of silent inactivation and allergic reaction to asparaginase (ASP) and its impact on treatment results in patients with lymphoblastic leukaemia. Material and methods: Seventy patients with acute lymphoblastic leukaemia treated with ASP were enrolled in the study. Asparaginase activity was monitored. The patients were switched to another ASP formulation after allergy or inactivation. The treatment results were analysed. Results: Silent inactivation of native E. coli ASP was diagnosed in 5 patients (7%) and allergy in 34 patients (49%), and these patients were switched to pegylated ASP (PEG-ASP). Silent inactivation of PEG-ASP occurred in 8 patients (23%) and allergy in 6 patients (17%). Eight children continued therapy with Erwinase, and 4 did not switch to Erwinase after inactivation of PEGASP. Allergy to Erwinase occurred in 2 patients (22%); there was no inactivation. No significant differences in outcome were found between the groups of patients with and without allergy or silent inactivation of ASP. Due to regular monitoring and switching to other ASP preparations after allergy or silent inactivation, therapeutic activity was ensured in almost all patients. Conclusions: Monitoring of ASP activity is crucial to recognize silent inactivation and to guarantee treatment effectiveness by switching to other ASP preparations. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

8. Development of treatment and clinical results in childhood acute myeloid leukemia in Poland

Author

Balwierz, Walentyna, Pawinska-Wasikowska, Katarzyna, Klekawka, Tomasz, Czogala, Malgorzata, Matysiak, Michal, Fic-Sikorska, Barbara, Adamkiewicz-Drozynska, Elzbieta, Maciejka-Kapuscinska, Lucyna, Chybicka, Alicja, Potocka, Kinga, Wachowiak, Jacek, Skalska-Sadowska, Jolanta, Kowalczyk, Jerzy, Wojcik, Beata, Wysocki, Mariusz, Koltan, Sylwia, Krawczuk-Rybak, Maryna, Muszynska-Roslan, Katarzyna, Mlynarski, Wojciech, Stolarska, Malgorzata, Urasinski, Tomasz, Kamienska, Elzbieta, Szczepanski, Tomasz, Tomaszewska, Renata, Sobol, Grazyna, Mizia-Malarz, Agnieszka, Karolczyk, Grazyna, Podhorecka, Joanna, Wieczorek, Maria, Karpinska-Derda, Irena, Badowska, Wanda, and Moryl-Bujakowska, Angelina

Published
2013
Full Text
View/download PDF

9. High Frequency of Fusion Gene Transcript Resulting From t(10;11)(p12;q23) Translocation in Pediatric Acute Myeloid Leukemia in Poland

Author

Ksiazek, Teofila, primary, Czogala, Malgorzata, additional, Kaczowka, Przemyslaw, additional, Sadowska, Beata, additional, Pawinska-Wasikowska, Katarzyna, additional, Bik-Multanowski, Mirosław, additional, Sikorska-Fic, Barbara, additional, Matysiak, Michał, additional, Skalska-Sadowska, Jolanta, additional, Wachowiak, Jacek, additional, Rodziewicz-Konarska, Anna, additional, Chybicka, Alicja, additional, Muszynska-Rosłan, Katarzyna, additional, Krawczuk-Rybak, Maryna, additional, Grabowski, Dominik, additional, Kowalczyk, Jerzy, additional, Maciejka-Kemblowska, Lucyna, additional, Adamkiewicz-Drozynska, Elzbieta, additional, Mlynarski, Wojciech, additional, Tomaszewska, Renata, additional, Szczepanski, Tomasz, additional, Pohorecka, Joanna, additional, Karolczyk, Grazyna, additional, Mizia-Malarz, Agnieszka, additional, Mycko, Katarzyna, additional, Badowska, Wanda, additional, Zielezinska, Karolina, additional, Urasinski, Tomasz, additional, Karpinska-Derda, Irena, additional, Woszczyk, Mariola, additional, Ciebiera, Małgorzata, additional, Lejman, Monika, additional, Skoczen, Szymon, additional, and Balwierz, Walentyna, additional

Published
2020
Full Text
View/download PDF

10. Retrospective Analysis of the Treatment Outcome in Myeloid Leukemia of Down Syndrome in Polish Pediatric Leukemia and Lymphoma Study Group From 2005 to 2019

Author

Czogala, Malgorzata, primary, Pawinska-Wasikowska, Katarzyna, additional, Ksiazek, Teofila, additional, Sikorska-Fic, Barbara, additional, Matysiak, Michal, additional, Skalska-Sadowska, Jolanta, additional, Wachowiak, Jacek, additional, Rodziewicz-Konarska, Anna, additional, Chybicka, Alicja, additional, Myszynska-Roslan, Katarzyna, additional, Krawczuk-Rybak, Maryna, additional, Grabowski, Dominik, additional, Kowalczyk, Jerzy, additional, Maciejka-Kemblowska, Lucyna, additional, Adamkiewicz-Drozynska, Elzbieta, additional, Bobeff, Katarzyna, additional, Mlynarski, Wojciech, additional, Tomaszewska, Renata, additional, Szczepanski, Tomasz, additional, Pohorecka, Joanna, additional, Chodala-Grzywacz, Agnieszka, additional, Karolczyk, Grazyna, additional, Mizia-Malarz, Agnieszka, additional, Mycko, Katarzyna, additional, Badowska, Wanda, additional, Zielezinska, Karolina, additional, Urasinski, Tomasz, additional, Nykiel, Magdalena, additional, Woszczyk, Mariola, additional, Ciebiera, Malgorzata, additional, Chaber, Radosław, additional, Skoczen, Szymon, additional, and Balwierz, Walentyna, additional

Published
2020
Full Text
View/download PDF

11. Polymorphisms of SLC19A1 80 G>A, MTHFR 677 C>T, and Tandem TS Repeats Influence Pharmacokinetics, Acute Liver Toxicity, and Vomiting in Children With Acute Lymphoblastic Leukemia Treated With High Doses of Methotrexate

Author

Cwiklinska, Magdalena, primary, Czogala, Malgorzata, additional, Kwiecinska, Kinga, additional, Madetko-Talowska, Anna, additional, Szafarz, Malgorzata, additional, Pawinska, Katarzyna, additional, Wieczorek, Aleksandra, additional, Klekawka, Tomasz, additional, Rej, Magdalena, additional, Stepien, Konrad, additional, Halubiec, Przemyslaw, additional, Lazarczyk, Agnieszka, additional, Miklusiak, Karol, additional, Bik-Multanowski, Miroslaw, additional, Balwierz, Walentyna, additional, and Skoczen, Szymon, additional

Published
2020
Full Text
View/download PDF

12. Unsatisfactory Outcome of Pediatric Relapsed and Refractory AML Treated with Clofarabine Combined with Topotecan, Vinorelbine and Thiotepa (TVTC)

Author

Skalska-Sadowska, Jolanta, primary, Pieczonka, Anna, additional, Smalisz-Skrzypczyk, Katarzyna, additional, Matysiak, Michal, additional, Muszynska-Roslan, Katarzyna, additional, Krawczuk-Rybak, Maryna, additional, Drabko, Katarzyna, additional, Kowalczyk, Jerzy, additional, Czogala, Malgorzata, additional, Balwierz, Walentyna, additional, Karolczyk, Grazyna, additional, Karpinska-Derda, Irena, additional, Woszczyk, Mariola, additional, Szczepanski, Tomasz, additional, and Wachowiak, Jacek, additional

Published
2015
Full Text
View/download PDF

13. Development of treatment and clinical results in childhood acute myeloid leukemia in Poland

Author

Balwierz, Walentyna, primary, Pawinska-Wasikowska, Katarzyna, additional, Klekawka, Tomasz, additional, Czogala, Malgorzata, additional, Matysiak, Michal, additional, Fic-Sikorska, Barbara, additional, Adamkiewicz-Drozynska, Elzbieta, additional, Maciejka-Kapuscinska, Lucyna, additional, Chybicka, Alicja, additional, Potocka, Kinga, additional, Wachowiak, Jacek, additional, Skalska-Sadowska, Jolanta, additional, Kowalczyk, Jerzy, additional, Wojcik, Beata, additional, Wysocki, Mariusz, additional, Koltan, Sylwia, additional, Krawczuk-Rybak, Maryna, additional, Muszynska-Roslan, Katarzyna, additional, Mlynarski, Wojciech, additional, Stolarska, Malgorzata, additional, Urasinski, Tomasz, additional, Kamienska, Elzbieta, additional, Szczepanski, Tomasz, additional, Tomaszewska, Renata, additional, Sobol, Grazyna, additional, Mizia-Malarz, Agnieszka, additional, Karolczyk, Grazyna, additional, Podhorecka, Joanna, additional, Wieczorek, Maria, additional, Karpinska-Derda, Irena, additional, Badowska, Wanda, additional, and Moryl-Bujakowska, Angelina, additional

Published
2012
Full Text
View/download PDF

14. Improvement of the Treatment Results in Childhood Acute Myeloid Leukemia in Poland from 1983 to 2017

Author

Balwierz, Walentyna, Czogala, Malgorzata, Pawinska-Wasikowska, Katarzyna, Wachowiak, Jacek, Skalska-Sadowska, Jolanta, Michał Matysiak, Szczepanski, Tomasz, Tomaszewska, Renata, Krawczuk-Rybak, Maryna, Muszynska-Roslan, Katarzyna, Kowalczyk, Jerzy R., Wisniewska-Slusarz, Hanna, Mlynarski, Wojciech, Chybicka, Alicja, Rodziewicz, Anna, Urasinski, Tomasz, Adamkiewicz-Drozynska, Elzbieta, Maciejka-Kemblowska, Lucyna, Karolczyk, Grazyna, Karpinska-Derda, Irena, Przybyszewski, Borys, Malarz-Mizia, Agnieszka, Koltan, Sylwia, and Chaber, Radoslaw

15. Improvement of the Treatment Results in Childhood Acute Myeloid Leukemia in Poland from 1983 to 2017

Author

Balwierz, Walentyna, Czogala, Malgorzata, Pawinska-Wasikowska, Katarzyna, Wachowiak, Jacek, Skalska-Sadowska, Jolanta, Matysiak, Michal, Szczepanski, Tomasz, Tomaszewska, Renata, Krawczuk-Rybak, Maryna, Muszynska-Roslan, Katarzyna, Kowalczyk, Jerzy R., Wisniewska-Slusarz, Hanna, Mlynarski, Wojciech, Chybicka, Alicja, Rodziewicz, Anna, Urasinski, Tomasz, Adamkiewicz-Drozynska, Elzbieta, Maciejka-Kemblowska, Lucyna, Karolczyk, Grazyna, Karpinska-Derda, Irena, Przybyszewski, Borys, Malarz-Mizia, Agnieszka, Koltan, Sylwia, and Chaber, Radoslaw

Abstract

Introduction: Acute myeloid leukemia (AML), heterogeneous group of malignant neoplasm of hematopoietic system, comprises of 15% of all leukemias in children. Standardized AML-BFM based protocols of the treatment of AML introduced in Poland from 1983 enabled successive improvement of survival rates. Before 1983 only 10% of children with AML in our country had chance to survive.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results